Description
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses in understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.15 - 0.66
Trade Value (12mth)
AU$9,705.00
1 week
4.35%
1 month
11.63%
YTD
-57.14%
1 year
-58.97%
All time high
2.05
EPS 3 yr Growth
72.400%
EBITDA Margin
N/A
Operating Cashflow
-$7m
Free Cash Flow Return
-27.60%
ROIC
-31.20%
Interest Coverage
N/A
Quick Ratio
14.50
Shares on Issue (Fully Dilluted)
75m
HALO Sector
Healthcare
Next Company Report Date
15-Aug-24
Ex Dividend Date (est.)
08-Dec-23
Next Dividend Pay Date (est.)
18-Dec-23
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 January 22 |
New Executive Director and Chairman Agreements
×
New Executive Director and Chairman Agreements |
31 August 23 |
Becoming a substantial holder
×
Becoming a substantial holder |
30 September 22 |
Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
×
Second HREC Approval for IIH EVOLVE Phase III Clinical Trial |
30 November 23 |
Payment of Capital Return Proceeds
×
Payment of Capital Return Proceeds |
30 November 22 |
Invex to Present at the MST Financial Biotech Forum
×
Invex to Present at the MST Financial Biotech Forum |
29 June 22 |
Invex Receives UK Approval to Commence Phase III Trial
×
Invex Receives UK Approval to Commence Phase III Trial |
29 June 20 |
Presentation of Exenatide Phase II Data at Headache Congress
×
Presentation of Exenatide Phase II Data at Headache Congress |
28 September 23 |
Change in substantial holding
×
Change in substantial holding |
28 November 23 |
Change in substantial holding
×
Change in substantial holding |
28 November 23 |
Chair's Address to Shareholders
×
Chair's Address to Shareholders |
28 November 23 |
Results of Meeting
×
Results of Meeting |
28 June 23 |
Phase III Clinical Trial Update and New IIH Market Analysis
×
Phase III Clinical Trial Update and New IIH Market Analysis |
28 August 20 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
27 September 21 |
Notice of Investor Call and Presentation
×
Notice of Investor Call and Presentation |
27 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
27 November 23 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
27 August 21 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
26 October 22 |
Upcoming Presentation at Argonaut Biotech Briefing
×
Upcoming Presentation at Argonaut Biotech Briefing |
25 September 23 |
Date of AGM and Closing Date for Director Nominations
×
Date of AGM and Closing Date for Director Nominations |
25 October 21 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
25 November 22 |
MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
×
MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ |
25 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
25 August 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
24 October 22 |
First Australian Site Activated in IIH EVOLVE Phase 3
×
First Australian Site Activated in IIH EVOLVE Phase 3 |
24 October 22 |
First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
×
First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial |
24 October 22 |
September Appendix 4C and Investor Conference Call Details
×
September Appendix 4C and Investor Conference Call Details |
24 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.